In the 1980s, a mere handful of drugs were licensed for treating virus infections, primarily against herpesviruses. The 1990s saw a rush of new compounds being licensed for treating HIV, at first novel nucleoside analogues and later the protease inhibitors. By 2000, the number had increased to more than 20 with many more compounds in various stages of development and, by 2010, the number is likely to be well over 50. Initially, the majority of the most useful compounds were nucleoside analogues for treating herpesvirus, human immunodeficiency virus (HIV) and hepatitis-B virus (HBV) infections. However, an increasingly wide range of chemical structures have emerged including ion-channel blockers and neuraminidase inhibitors for influenza, capsid-binding proteins for picornaviruses, protease inhibitors for HIV and so on. There is now a bewildering array of antiviral compounds -some, such as acyclovir, azidothymidine and oseltamivir are set to be long-standing therapies that have already become very familiar compounds. However, other compounds have remained only briefly in the clinical arena until lack of clinical efficacy or unacceptable toxicity was recognized. Some of these are not widely known.
The idea of assembling current antiviral agents into single convenient document was conceived early in 1995. The first 'Current antiviral agents FactFile' comprising some 30 compounds active against herpesviruses, hepatitis viruses and respiratory viruses, was published in International Antiviral News and was soon followed by an article documenting a further 30 compounds with anti-HIV activity . The original objective of these publications was to provide a handy document as an aide mémoire for use at scientific meetings, or to keep handy when writing or working on antiviral documents. It would thus be a rapid key to the vital statistics of all the relevant compounds in a convenient format. An international team of authors worked on subsequent editions of the FactFile and the sixth and final version in the original format appeared in International Antiviral News in 2001 (Kinchington et al., 2000; Kinchington et al., 2001) . By this time it had expanded to include 118 compounds (70 for HIV; 26 for herpesviruses; 11 for HBV; 7 for influenza viruses and 2 each for hepatitis-C virus and papillomavirus). Since 2001 the FactFile has languished, but there have been an increasing number of calls for the document to be revived, updated and republished in a modernised form.
To address these demands, the Editors of Antiviral Chemistry and Chemotherapy decided last year to revitalize the project. The layout of the 2006 version of the Antiviral FactFile has been completely reconfigured although it is still based on the original concept. The criteria for inclusion confine the entries to those compounds that have undergone or are about to undergo at least Phase I clinical trials; an investigational new drug (IND) application must have been granted. This includes several compounds that were subsequently withdrawn from further development, but excludes compounds that have not been tested in man and for which there is little prospect for human or veterinary use in the foreseeable future.
In the current FactFile, the antiviral compounds are listed alphabetically according to their generic names. However, with the increasing number of different susceptible viruses, it seemed logical to subdivide the list into three sections according to the major groups of virus families. Thus, the list comprises three groups of compound whose primary target are: i) the DNA viruses: Herpesviridae, Poxviridae, The chemical structure for each compound is also reported, with the configuration of key chiral centres correctly represented, while nucleoside analogues are shown in their customary representation. For clarity, most of the compounds are presented with their commonly used names, whereas IUPAC nomenclature has been used in those few cases where it was considered more informative.
Editorial

Antiviral Chemistry & Chemotherapy's current antiviral agents FactFile 2006 (1st edition)
Undoubtedly, this FactFile is in an active phase of expansion. The current version includes new compounds presented at the recent International Conference on Antiviral Research (ICAR) meeting in San Juan, Puerto Rico (7-11 May, 2006) . Peramivir (BioCryst Pharmaceuticals Inc., formerly RWJ-270201) for influenza failed to progress following disappointing Phase III trial, but the threat of H5N1 influenza has stimulated renewed interest. Perhaps an oral prodrug would have useful antiinfluenza activity in clinical use? An inhibitor of influenza RNA polymerase, T-705 (Toyama Chemical Co., Ltd) has shown impressive activity in animal models and is likely to enter clinical trials soon. R1479 (Roche) showed sufficient activity in hepatitis C virus-infected patients to encourage the development of the oral prodrug R1626. ST-246 (SIGA Technologies Inc.) was discovered and developed as part of the programme to prepare against bioterrorism. It is highly active against poxviruses, seems to have little toxicity and has been tested in two dose cohorts in Phase I trial without any problems.
Other ICAR presentations described the continuing progression of compounds which seem likely candidates for the next FactFile update. These include BCX 2798 (BioCryst Pharmaceuticals Inc.) for parainfluenza, an oral prodrug of Cf1743 (Welsh School of Pharmacy, Cardiff, UK) for herpes zoster, fludase (NexBio Inc.) for influenza and GS 9131, a prodrug of GS 9148, (Gilead Sciences Inc.) for HIV strains resistant against most other nucleoside antivirals. Rep 9 (Replicor Inc.) binds to the fusion portion of enveloped viruses and has demonstrated broad antiviral activity against influenza A and B (including A/H5N1 strains), HIV, herpes simplex virus, cytomegalovirus and respiratory syncytial virus.
Our ultimate aim for the FactFile is to include it on Antiviral Chemistry & Chemotherapy's web site so that our subscribers can see the updated version at any time.
